CL2009000523A1 - Preparacion de 1-[3-(3,4-diclorofenil)prop-2-in-1-il o alil]-1h-indol-2,3-diona por reaccion entre ya sea 1-alil o 1-prop-2-in-1-il-1h-indol-2,3-diona con un trihalo benceno; y los compuestos intermediarios considerados. - Google Patents

Preparacion de 1-[3-(3,4-diclorofenil)prop-2-in-1-il o alil]-1h-indol-2,3-diona por reaccion entre ya sea 1-alil o 1-prop-2-in-1-il-1h-indol-2,3-diona con un trihalo benceno; y los compuestos intermediarios considerados.

Info

Publication number
CL2009000523A1
CL2009000523A1 CL2009000523A CL2009000523A CL2009000523A1 CL 2009000523 A1 CL2009000523 A1 CL 2009000523A1 CL 2009000523 A CL2009000523 A CL 2009000523A CL 2009000523 A CL2009000523 A CL 2009000523A CL 2009000523 A1 CL2009000523 A1 CL 2009000523A1
Authority
CL
Chile
Prior art keywords
dione
indole
prop
allyl
preparation
Prior art date
Application number
CL2009000523A
Other languages
English (en)
Spanish (es)
Inventor
Carmen Leung
Miroslaw Tomaszewki
Simon Woo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2009000523A1 publication Critical patent/CL2009000523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
CL2009000523A 2006-02-07 2009-03-05 Preparacion de 1-[3-(3,4-diclorofenil)prop-2-in-1-il o alil]-1h-indol-2,3-diona por reaccion entre ya sea 1-alil o 1-prop-2-in-1-il-1h-indol-2,3-diona con un trihalo benceno; y los compuestos intermediarios considerados. CL2009000523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
CL2009000523A1 true CL2009000523A1 (es) 2009-07-17

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000523A CL2009000523A1 (es) 2006-02-07 2009-03-05 Preparacion de 1-[3-(3,4-diclorofenil)prop-2-in-1-il o alil]-1h-indol-2,3-diona por reaccion entre ya sea 1-alil o 1-prop-2-in-1-il-1h-indol-2,3-diona con un trihalo benceno; y los compuestos intermediarios considerados.

Country Status (21)

Country Link
US (2) US20070185179A1 (https=)
EP (1) EP2013215A4 (https=)
JP (1) JP2009526043A (https=)
KR (1) KR20080094906A (https=)
CN (1) CN101415711A (https=)
AR (1) AR059265A1 (https=)
AU (1) AU2007212786B2 (https=)
BR (1) BRPI0707423A2 (https=)
CA (1) CA2641632A1 (https=)
CL (1) CL2009000523A1 (https=)
IL (1) IL192890A0 (https=)
NO (1) NO20083547L (https=)
NZ (1) NZ571070A (https=)
RU (1) RU2421457C2 (https=)
SA (1) SA07280027B1 (https=)
SG (1) SG169387A1 (https=)
TW (1) TW200801011A (https=)
UA (1) UA93226C2 (https=)
UY (1) UY30132A1 (https=)
WO (1) WO2007091947A2 (https=)
ZA (1) ZA200806407B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
HUP0203548A3 (en) * 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
US7879866B2 (en) 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
WO2007091948A2 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Also Published As

Publication number Publication date
SA07280027B1 (ar) 2010-11-22
AU2007212786A1 (en) 2007-08-16
AU2007212786A8 (en) 2010-05-06
IL192890A0 (en) 2009-02-11
NZ571070A (en) 2011-07-29
WO2007091947A8 (en) 2008-08-07
AU2007212786B2 (en) 2011-06-02
RU2008131905A (ru) 2010-03-20
EP2013215A2 (en) 2009-01-14
US7868181B2 (en) 2011-01-11
ZA200806407B (en) 2009-04-29
CN101415711A (zh) 2009-04-22
EP2013215A4 (en) 2010-09-08
BRPI0707423A2 (pt) 2011-05-03
RU2421457C2 (ru) 2011-06-20
NO20083547L (no) 2008-11-05
WO2007091947A3 (en) 2007-10-04
SG169387A1 (en) 2011-03-30
KR20080094906A (ko) 2008-10-27
JP2009526043A (ja) 2009-07-16
TW200801011A (en) 2008-01-01
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
US20090137650A1 (en) 2009-05-28
AR059265A1 (es) 2008-03-19
WO2007091947A2 (en) 2007-08-16
UA93226C2 (en) 2011-01-25
US20070185179A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
MA29686B1 (fr) Sels de 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
DE602005020837D1 (de) Il-7-varianten mit reduzierter immunogenität
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
TW200745125A (en) Novel imide derivative, material for organic electroluminescent element, and organic electroluminescent element comprising the same
ATE496933T1 (de) Reines rocuroniumbromid
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TN2010000148A1 (en) Amide compound
EP1797034A4 (en) SULFONYL COMPOUNDS AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
NO20051270L (no) Sammensmeltet benzenderivat og anvendelse
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
ATE435206T1 (de) Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
IL186809A0 (en) Solid forms of 1-(5-(ih-i,2,4-triazol-5-yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
TW200616965A (en) Synthesis of n2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
WO2007062151A3 (en) Chemical compounds
WO2007062148A3 (en) Chemical compounds
TW200833660A (en) Synthesis of pyrrolidine compounds
WO2007062145A3 (en) Chemical compounds
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
MXPA05013652A (es) Modulador del receptor canabinoide.
SV2007002422A (es) Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol, su preparacion y su aplicacion en terapeutica.
WO2007062190A3 (en) Chemical compounds
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
CL2009000523A1 (es) Preparacion de 1-[3-(3,4-diclorofenil)prop-2-in-1-il o alil]-1h-indol-2,3-diona por reaccion entre ya sea 1-alil o 1-prop-2-in-1-il-1h-indol-2,3-diona con un trihalo benceno; y los compuestos intermediarios considerados.
TW200740769A (en) Novel process